Hansa Biopharma — Februar 2026
-
Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
11 Feb 2026, 07:00
Regulatory information· Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024.
· Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation.
· Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M). -
Full‑year 2025 IDEFIRIX product sales amounted to 204.7 MSEK for the full year, a 46% increase from 140.1 MSEK in the previous year. Revenue totalled 222.3 MSEK, representing a 30% increase compared to 171.3 MSEK in 2024. This growth reflects continued adoption across major European markets and underscores both the clinical value of IDEFIRIX, and the momentum Hansa is building in the treatment of highly sensitized patients undergoing kidney transplantation
-
Interim Report
January - December 2025https://www.hansabiopharma.com/files/Main/1219/4305662/hnsa--q4-2025-eng-final.pdf
-
Analysts and consensus | Hansa Biopharma
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
(www.hansabiopharma.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind